Takao Suga
Overview
Explore the profile of Takao Suga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamano N, Komaba H, Tanaka H, Takahashi H, Takahashi Y, Hyodo T, et al.
Am J Nephrol
. 2025 Feb;
:1-9.
PMID: 39978330
Introduction: Recent experimental studies have reported that fibroblast growth factor 23 (FGF23) inhibits erythropoiesis by suppressing erythropoietin (EPO) production and downregulating the EPO receptor. Conversely, either endogenous or exogenous EPO...
2.
Soeda K, Komaba H, Nakagawa Y, Kawabata C, Wada T, Takahashi H, et al.
J Nephrol
. 2024 Mar;
37(5):1339-1349.
PMID: 38512372
Background: Hyponatremia is implicated in pathological bone resorption and has been identified as a risk factor for bone fracture in the general population. However, there are limited data on the...
3.
Nakagawa Y, Komaba H, Wada T, Takahashi H, Takahashi Y, Hyodo T, et al.
Am J Nephrol
. 2022 Dec;
53(11-12):767-774.
PMID: 36574760
Introduction: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure. Sclerostin might be involved in the pathogenesis of vascular calcification, but few studies have examined...
4.
Nakagawa Y, Komaba H, Hamano N, Tanaka H, Wada T, Ishida H, et al.
J Clin Endocrinol Metab
. 2021 Aug;
107(1):e95-e105.
PMID: 34423837
Context: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure, but its role in the pathogenesis of renal bone disease remains unknown. Objective: We aimed...
5.
Nakagawa Y, Komaba H, Hamano N, Wada T, Hida M, Suga T, et al.
Kidney Int
. 2020 Jul;
98(4):970-978.
PMID: 32682522
The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline update suggests bone mineral density testing to assess fracture risk in patients with chronic kidney disease, but dual-energy X-ray absorptiometry is...
6.
Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M
Nephrol Dial Transplant
. 2018 Apr;
34(2):318-325.
PMID: 29672760
Background: Hyperphosphatemia and poor nutritional status are associated with increased mortality. Lanthanum carbonate is an effective, calcium-free phosphate binder, but little is known about the long-term impact on mineral metabolism,...
7.
Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M
Nephrol Dial Transplant
. 2014 Nov;
30(1):107-14.
PMID: 25422311
Background: Lanthanum carbonate is a non-calcium phosphate binder that is effective for the treatment of hyperphosphatemia. However, it is unknown whether treatment with lanthanum affects survival. Methods: We retrospectively collected...
8.
Takahashi H, Sawada K, Kakuta T, Suga T, Hanai K, Kanai G, et al.
J Artif Organs
. 2013 May;
16(3):368-75.
PMID: 23666226
Bioartificial renal tubule devices (BTD) use cell therapy to improve conditions commonly observed in recipients of artificial kidneys for treatment of kidney diseases. We previously reported significant improvement of the...
9.
Suzuki D, Toyoda M, Umezono T, Uehara G, Zhang S, Sakai T, et al.
Nephrology (Carlton)
. 2004 Mar;
8(2):92-7.
PMID: 15012739
Connective tissue growth factor (CTGF) is a cysteine-rich member of a new family of growth regulators. It is an important factor in the pathogenesis of mesangial matrix accumulation and progressive...